Long Run Wealth Advisors’s AbbVie ABBV Stock Holding History

Long Run Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$264K	Buy	1,153 +7	+0.6%	+$1.59K	0.05%	95
2025 Q3	$265K	Buy	1,146 +8	+0.7%	+$1.63K	0.05%	93
2025 Q2	$211K	Buy	1,138 +10	+0.9%	+$1.86K	0.04%	100
2025 Q1	$236K	Buy	+1,128	New	+$219K	0.05%	94
2024 Q4	–	Sell	-1,277	Closed	-$252K	–	99
2024 Q3	$252K	Sell	1,277 -378	-23%	-$70.5K	0.06%	91
2024 Q2	$284K	Sell	1,655 -322	-16%	-$53.3K	0.07%	85
2024 Q1	$360K	Sell	1,977 -200	-9%	-$34.5K	0.09%	79
2023 Q4	$337K	Sell	2,177 -96	-4%	-$14K	0.1%	77
2023 Q3	$339K	Buy	2,273 +11	+0.5%	+$1.61K	0.11%	72
2023 Q2	$305K	Hold	2,262	–	–	0.1%	79
2023 Q1	$360K	Hold	2,262	–	–	0.12%	79
2022 Q4	$366K	Hold	2,262	–	–	0.13%	80
2022 Q3	$304K	Hold	2,262	–	–	0.12%	79
2022 Q2	$346K	Hold	2,262	–	–	0.13%	75
2022 Q1	$368K	Hold	2,262	–	–	0.13%	77
2021 Q4	$306K	Buy	+2,262	New	+$267K	0.11%	83

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Long Run Wealth Advisors's ABBV Position: Q4 2025 in Review

Long Run Wealth Advisors increased its AbbVie (ABBV) stake by 0.61% in Q4 2025, buying an estimated $1.59K and bringing the position to 1,153 shares worth $264K. The position accounts for 0.05% of the portfolio, ranked #95.

Long Run Wealth Advisors first reported a position in ABBV in Q4 2021 and has held it in 16 quarters since. The position peaked at $368K in Q1 2022. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Long Run Wealth Advisors held 1,153 shares of AbbVie worth $264K as of Q4 2025.
Long Run Wealth Advisors bought 7 AbbVie shares in Q4 2025, an estimated $1.59K.
AbbVie made up 0.05% of Long Run Wealth Advisors's portfolio in Q4 2025, its #95 holding.
Long Run Wealth Advisors first reported a position in AbbVie in Q4 2021 and has held it in 16 quarters since.
Long Run Wealth Advisors's AbbVie position peaked at $368K in Q1 2022.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Long Run Wealth Advisors's 13F filing for Q4 2025, filed 2 Feb 2026.